P01834 (IGKC_HUMAN) Homo sapiens (Human)
Immunoglobulin kappa constant UniProtKBAFDB90v4InterProInteractive Modelling
107 aa; Sequence (Fasta) ;
1 identical sequence: Cyprinus carpio: A0A8C2JGN2
It is possible new templates exist for this target since these models were created.
Available Structures
66 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of broadly and potently neutralizing antibody VRC08 in complex with HIV-1 clade A… |
Heteromer P01857; Q8JDI3; | 11×NAG; 2×BU3; | ||||
| Assess | ||||||
| Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope |
Heteromer P0DOX5; | 8×GOL; 4×SO4; 1×CXS; 1×K; | ||||
| Assess | ||||||
| Trastuzumab Fab v3 |
Heteromer P02976; Q51918; S6B291; | |||||
| Assess | ||||||
| Trastuzumab Fab v3 with 5-diphenyl meditope variant |
Heteromer P02976; Q51918; Q6GMX6; | |||||
| Assess | ||||||
| Crystal structure of human anti-tau antibody CBTAU-27.1 |
Heteromer P01857; | 2×GOL; | ||||
| Assess | ||||||
| 48G7 HYBRIDOMA LINE FAB COMPLEXED WITH HAPTEN 5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID |
Heteromer P01857; | 1×NPE; | ||||
| Assess | ||||||
| Trastuzumab Fab v3 in complex with 5-phenyl meditope variant |
Heteromer P02976; Q51918; Q6GMX6; | |||||
| Assess | ||||||
| Trastuzumab Fab v3 in complex with CQFDLSTRRLKC |
Heteromer P02976; Q51918; S6B291; | |||||
| Assess | ||||||
| Crystal structure of a humanised 3D6 Fab bound to amyloid beta peptide |
Heteromer P01857; P05067; | |||||
| Assess | ||||||
| ANTIBODY GNC92H2 BOUND TO LIGAND |
Heteromer P01857; | 1×COC; | ||||
| Assess | ||||||
| HIV-1 gp120 Envelope Glycoprotein Complexed with the Broadly Neutralizing CD4-Binding-Site Antibody… |
Heteromer P04578; | 13×NAG; | ||||
| Assess | ||||||
| Crystal structure of broadly and potently neutralizing antibody VRC08C in complex with HIV-1 clade … |
Heteromer P01857; Q8JDI3; | 11×NAG; | ||||
| Assess | ||||||
| Crystal structure of a Fab binding to extracellular domain 5 of Cadherin-6 |
Heteromer P55285; S6B291; | 1×SIN; 2×A2G; | ||||
| Assess | ||||||
| Structure of NIH45-46 Fab in complex with gp120 of 93TH057 HIV |
Heteromer A0A0M3KKW9; P01857; | 1×NAG; 1×FLC; 6×NAG; 1×CL; | ||||
| Assess | ||||||
| IGG FAB (HUMAN IGG1, KAPPA) CHIMERIC FRAGMENT (CBR96) COMPLEXED WITH LEWIS Y NONOATE METHYL ESTER |
Heteromer | 1×NAG; 1×NON; | ||||
| Assess | ||||||
| STRUCTURE OF UNCOMPLEXED FAB COMPARED TO COMPLEX (1CLY, 1CLZ) |
Heteromer | 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of NIH45-46 Fab |
Heteromer P01857; | 3×GOL; 1×SO4; 1×NAG; | ||||
| Assess | ||||||
| FREE AND LIGANDED FORM OF AN ESTEROLYTIC CATALYTIC ANTIBODY |
Heteromer P01857; | |||||
| Assess | ||||||
| Structure of P. magnus protein L bound to a human IgM Fab. |
Heteromer P01871; Q51918; | 2×IMD; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE INTACT HUMAN IGG B12 WITH BROAD AND POTENT ACTIVITY AGAINST PRIMARY HIV-1 … |
Heteromer P01857; | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| STRUCTURE OF A HUMAN MONOCLONAL ANTIBODY FAB FRAGMENT AGAINST GP41 OF HUMAN IMMUNODEFICIENCY VIRUS … |
Heteromer P01857; | |||||
| Assess | ||||||
| Anti-beta-amyloid antibody c706 fab in space group c2 |
Heteromer P01857; | |||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B |
Heteromer A0A5C2G1U0; P0DP01; P0DTC2; V9HW68; | 22×NAG; 3×NAG; 27×NAG; | ||||
| Assess | ||||||
| Structure of human B-cell antigen receptor of the IgM isotype |
Heteromer P01871; P11912; P40259; | 14×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B |
Heteromer A0A5C2G1U0; P0DP01; P0DTC2; V9HW68; | 21×NAG; 2×NAG; 28×NAG; | ||||
| Assess | ||||||
| Structure of IgE bound to the ectodomain of FceRIa |
Heteromer P01854; P12319; | 2×NAG; 2×NAG; 3×NAG; 2×NAG; | ||||
| Assess | ||||||
| CryoEM structure of Hantavirus ANDV Gn(H) protein complex with 2Fabs ANDV-5 and ANDV-34 |
Heteromer P0DOX5; Q9E006; | |||||
| Assess | ||||||
| Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex |
Heteromer P04626; P0DOX5; Q6GMX6; | 1×NAG; 5×NAG; | ||||
| Assess | ||||||
| Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (14:0) |
Heteromer Q6N089; | 1×NKN; | ||||
| Assess | ||||||
| Crystal structure of human anti-tau antibody CBTAU-27.1 Fab in complex with a human tau peptide |
Heteromer A0A2K5IAM2; P01857; | |||||
| Assess | ||||||
| Crystal structure of the humanized apo LT3015 anti-lysophosphatidic acid antibody Fab fragment |
Heteromer Q6N089; | 2×SO4; 1×PGE; | ||||
| Assess | ||||||
| Crystal Structure of mid-region amyloid beta capture by solanezumab |
Heteromer P01857; P05067; | |||||
| Assess | ||||||
| Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D |
Heteromer P00746; P01857; | |||||
| Assess | ||||||
| Crystal structure of the LT3015 antibody Fab fragment in complex with lysophosphatidic acid (18:2) |
Heteromer Q6N089; | 1×18L; | ||||
| Assess | ||||||
| IGG FAB FRAGMENT (CD25-BINDING) |
Heteromer | |||||
| Assess | ||||||
| Crystal structure of broadly neutralizing antibody CR8043 |
Heteromer S6C4S0; | 2×PEG; | ||||
| Assess | ||||||
| Crystal structure of SARS-CoV-2 spike stem fusion peptide in complex with neutralizing antibody COV… |
Heteromer P0DOX5; P0DTC2; | |||||
| Assess | ||||||
| Crystal Structure of Broadly Neutralizing Antibody CH03, Isolated from Donor CH0219, in Complex wit… |
Heteromer P44815; S6BGE0; W6ICC0; | 1×NAG; 1×NAG; 5×NAG; 2×NAG; 2×NAG; 3×ZN; 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of broadly and potently neutralizing antibody VRC06B in complex with HIV-1 clade … |
Heteromer P01857; Q0ED31; | 1×NAG; 6×NAG; | ||||
| Assess | ||||||
| Crystal Structure of Broadly Neutralizing Antibody CH04, Isolated from Donor CH0219, in Complex wit… |
Heteromer P44815; Q4QX31; | 1×NAG; 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 |
Heteromer Q2N0S6; Q8TCD0; S6B291; | 10×NAG; 18×NAG; 5×NAG; 3×NAG; 7×NAG; 1×NAG; 13×NAG; | ||||
| Assess | ||||||
| AD related murine antibody Fragment |
Heteromer P01647; P01808; P01857; | |||||
| Assess | ||||||
| Structure of an HIV epitope scaffold in complex with neutralizing antibody b12 Fab |
Heteromer | 4×GOL; | ||||
| Assess | ||||||
| DIELS ALDER CATALYTIC ANTIBODY GERMLINE PRECURSOR |
Heteromer | |||||
| Assess | ||||||
| DIELS ALDER CATALYTIC ANTIBODY WITH TRANSITION STATE ANALOGUE |
Heteromer | 2×CD; 1×FRA; | ||||
| Assess | ||||||
| Structure of cetuximab with aminoheptanoic acid-linked N-(3-hydroxypropyl)-L-arginine meditope vari… |
Heteromer S6B291; | 1×SO4; | ||||
| Assess | ||||||
| Structure of cetuximab with aminoheptanoic acid-linked N-(3-aminopropyl)-L-arginine meditope variant |
Heteromer S6B291; | |||||
| Assess | ||||||
| Structure of cetuximab with aminoheptanoic acid-linked N-carboxyethylarginine meditope variant |
Heteromer S6B291; | 1×SO4; | ||||
| Assess | ||||||
| Structure of cetuximab with aminoheptanoic acid-linked n-butylarginine meditope variant |
Heteromer S6B291; | 1×SO4; | ||||
| Assess | ||||||
| Structure of cetuximab with aminoheptanoic acid-linked n-octylarginine meditope variant |
Heteromer S6B291; | 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of the Human Fab VRC38.01, an HIV-1 V1V2-Directed Neutralizing Antibody Isolated … |
Heteromer Q6N089; | |||||
| Assess | ||||||
| CONFORMATION EFFECTS IN BIOLOGICAL CATALYSIS INTRODUCED BY OXY-COPE ANTIBODY MATURATION |
Heteromer P01857; | 4×CD; 1×HOP; | ||||
| Assess | ||||||
| UNLIGANDED GERMLINE PRECURSOR OF AN OXY-COPE CATALYTIC ANTIBODY |
Heteromer P01857; | 3×CD; | ||||
| Assess | ||||||
| UNLIGANDED MATURE OXY-COPE CATALYTIC ANTIBODY |
Heteromer P01857; | 1×CD; | ||||
| Assess | ||||||
| Crystal structure of the Fab fragment of therapeutic antibody Basiliximab in complex with IL-2Ra (C… |
Heteromer P01589; | 1×NAG; | ||||
| Assess | ||||||
| Crystal structure of broadly neutralizing antibody CR8043 bound to H3 influenza hemagglutinin |
Heteromer Q91MA7; S6C4S0; | 6×NAG; 8×NAG; | ||||
| Assess | ||||||
| Crystal structure BG505 SOSIP gp140 HIV-1 Env trimer bound to broadly neutralizing antibodies PGT12… |
Heteromer P01857; Q2N0S6; S6B291; | 12×NAG; 6×NAG; 3×NAG; 3×NAG; 3×NAG; 9×NAG; 3×NAG; 3×NAG; 18×NAG; 3×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF THE ANTIBODY 7B2 THAT CAPTURES HIV-1 VIRIONS |
Heteromer P04578; S6B291; | |||||
| Assess | ||||||
| Crystal structure of the NK1 domain of HGF in complex with anti-HGF monoclonal antibody SFN68. |
Heteromer P14210; U3KM01; | |||||
| Assess | ||||||
| Crystal structure of HLA-B*57:01.I80N |
Heteromer P01889; P61769; | |||||
| Assess | ||||||
| KIR3DL1 in complex with HLA-B*5701 |
Heteromer P01889; P43629; P61769; | 3×NAG; | ||||
| Assess | ||||||
| KIR3DL1 in complex with HLA-B*57:01.I80T |
Heteromer P01889; P43629; P61769; | 3×NAG; | ||||
| Assess | ||||||
| Crystal structure of HLA-B*57:01.I80N.L82R.R83G |
Heteromer P01889; P61769; | |||||
| Assess | ||||||
| KIR3DL1*005 in complex with HLA-B*57:01 |
Heteromer P01889; P43629; P61769; | 3×NAG; | ||||
| Assess | ||||||
| KIR3DL1*015 in complex with HLA-B*57:01 |
Heteromer P01889; P43629; P61769; | 3×NAG; | ||||
| Assess | ||||||
| Crystal Structure of HLA-B*5701, presenting the self peptide, LSSPVTKSF |
Heteromer P01889; P61769; | 4×GOL; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8dao.1.D | monomer | 0.89 | 100.00 | |||
| Assess | ||||||